A Review of Resistance Mechanisms to Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25105246 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kamil Wiśniewski und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Leukemia, Lymphocytic, Chronic, B-Cell, Drug Resistance, Neoplasm, Protein Kinase Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bruton’s Tyrosine Kinase (BTK) inhibitors have become one of the most vital drugs in the therapy of chronic lymphocytic leukemia (CLL). Inactivation of BTK disrupts the B-cell antigen receptor (BCR) signaling pathway, which leads to the inhibition of the proliferation and survival of CLL cells. BTK inhibitors (BTKi) are established as leading drugs in the treatment of both treatment-naïve (TN) and relapsed or refractory (R/R) CLL. Furthermore, BTKi demonstrate outstanding efficacy in high-risk CLL, including patients with chromosome 17p deletion, TP53 mutations, and unmutated status of the immunoglobulin heavy-chain variable region (IGHV) gene. Ibrutinib is the first-in-class BTKi which has changed the treatment landscape of CLL. Over the last few years, novel, covalent (acalabrutinib, zanubrutinib), and non-covalent (pirtobrutinib) BTKi have been approved for the treatment of CLL. Unfortunately, continuous therapy with BTKi contributes to the acquisition of secondary resistance leading to clinical relapse. In recent years, it has been demonstrated that the predominant mechanisms of resistance to BTKi are mutations in BTK or phospholipase Cγ2 (PLCG2). Some differences in the mechanisms of resistance to covalent BTKi have been identified despite their similar mechanism of action. Moreover, novel mutations resulting in resistance to non-covalent BTKi have been recently suggested. This article summarizes the clinical efficacy and the latest data regarding resistance to all of the registered BTKi.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.
ORCID-Profile: Kamil Wiśniewski, Bartosz Puła
Zitieren
APA
Wiśniewski, K., & Puła, B. (2024). A Review of Resistance Mechanisms to Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105246
Vancouver
Wiśniewski K, Puła B. A Review of Resistance Mechanisms to Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105246
BibTeX
@article{Winiewski2024,
author = {Wiśniewski, Kamil and Puła, Bartosz},
title = {A Review of Resistance Mechanisms to Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25105246}
}
EUVIMED